NYSE:BMY', 'Bristol-Myers Squibb Company', 'http://weeklyregister.com/weekly-register-logo.png');

Reaffirmed: Bristol Myers (NYSE:BMY) Buy Rating Reiterated by UBS; $72.0 Target in Place

December 7, 2017 - By Jacob Falcon

 Reaffirmed: Bristol Myers (NYSE:BMY) Buy Rating Reiterated by UBS; $72.0 Target in Place

Investors sentiment decreased to 0.95 in Q2 2017. Its down 0.03, from 0.98 in 2017Q1. It worsened, as 78 investors sold Bristol-Myers Squibb Company shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported.

Ecor1 Capital Ltd Liability Corporation holds 0.17% in Bristol-Myers Squibb Company (NYSE:BMY) or 17,060 shares. Hightower Advsrs Lc invested 0.56% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Brown Brothers Harriman has 93,895 shares for 0.03% of their portfolio. Hutchinson Mgmt Ca has invested 0.06% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Mcdaniel Terry Communication has 5,450 shares. Johnson Finance Grp Inc invested in 0.09% or 11,235 shares. Eagleclaw Cap Managment Lc holds 0.33% in Bristol-Myers Squibb Company (NYSE:BMY) or 10,222 shares. Orrstown Svcs reported 0.04% in Bristol-Myers Squibb Company (NYSE:BMY). Connecticut-based Halsey Associates Inc Ct has invested 0.06% in Bristol-Myers Squibb Company (NYSE:BMY). Fmr Ltd Liability Com has invested 0.25% in Bristol-Myers Squibb Company (NYSE:BMY). Duff Phelps Inv Co accumulated 0.02% or 18,895 shares. Great West Life Assurance Can reported 1.58 million shares. Advisers Limited Company, a California-based fund reported 280,833 shares. Smith Chas P Associate Pa Cpas has 8,144 shares for 0.07% of their portfolio. Goelzer Inc stated it has 0.52% in Bristol-Myers Squibb Company (NYSE:BMY).

Bristol Myers (NYSE:BMY) Rating Reaffirmed

UBS now has a $72.0 target price per share on shares of Bristol Myers (NYSE:BMY). The target price per share suggests a potential upside of 16.43 % from the last stock close price of Bristol Myers (NYSE:BMY). This rating was revealed in a research note on Friday, 6 October.

Investors sentiment decreased to 0.95 in Q2 2017. Its down 0.03, from 0.98 in 2017Q1. It worsened, as 78 investors sold Bristol-Myers Squibb Company shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported.

Ecor1 Capital Ltd Liability Corporation holds 0.17% in Bristol-Myers Squibb Company (NYSE:BMY) or 17,060 shares. Hightower Advsrs Lc invested 0.56% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Brown Brothers Harriman has 93,895 shares for 0.03% of their portfolio. Hutchinson Mgmt Ca has invested 0.06% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Mcdaniel Terry Communication has 5,450 shares. Johnson Finance Grp Inc invested in 0.09% or 11,235 shares. Eagleclaw Cap Managment Lc holds 0.33% in Bristol-Myers Squibb Company (NYSE:BMY) or 10,222 shares. Orrstown Svcs reported 0.04% in Bristol-Myers Squibb Company (NYSE:BMY). Connecticut-based Halsey Associates Inc Ct has invested 0.06% in Bristol-Myers Squibb Company (NYSE:BMY). Fmr Ltd Liability Com has invested 0.25% in Bristol-Myers Squibb Company (NYSE:BMY). Duff Phelps Inv Co accumulated 0.02% or 18,895 shares. Great West Life Assurance Can reported 1.58 million shares. Advisers Limited Company, a California-based fund reported 280,833 shares. Smith Chas P Associate Pa Cpas has 8,144 shares for 0.07% of their portfolio. Goelzer Inc stated it has 0.52% in Bristol-Myers Squibb Company (NYSE:BMY).

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. $62.53’s average target is 1.12% above currents $61.84 stock price. Bristol-Myers Squibb Company had 69 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Wednesday, October 18 by Citigroup. The company was maintained on Monday, October 23 by Leerink Swann. The rating was maintained by Barclays Capital on Friday, September 9 with “Equal-Weight”. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Buy” rating by Jefferies on Monday, December 19. Jefferies downgraded Bristol-Myers Squibb Company (NYSE:BMY) on Monday, October 16 to “Hold” rating. As per Friday, April 29, the company rating was maintained by Barclays Capital. Jefferies maintained the stock with “Hold” rating in Thursday, August 27 report. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Piper Jaffray on Friday, September 22. The firm earned “Hold” rating on Thursday, October 19 by Cowen & Co. UBS maintained the shares of BMY in report on Friday, August 19 with “Buy” rating.

The stock increased 1.43% or $0.87 during the last trading session, reaching $61.84. About 5.12M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since December 7, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on January, 25. They expect $0.67 earnings per share, up 6.35 % or $0.04 from last year’s $0.63 per share. BMY’s profit will be $1.10B for 23.07 P/E if the $0.67 EPS becomes a reality. After $0.75 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -10.67 % negative EPS growth.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $101.21 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 24.26 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Bloomberg.com which released: “Bristol-Myers Cancer Drug Opdivo Shows Surprising HIV Impact” on December 01, 2017, also Investorplace.com with their article: “Anemic Quant Score Restrict Bristol-Myers Squibb Co (BMY) Rating” published on November 24, 2017, Nasdaq.com published: “Madrona Financial Services, LLC Buys ONEOK Inc, Boeing Co, Bristol-Myers …” on November 09, 2017. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Investorplace.com and their article: “Bristol-Myers Squibb Co (BMY) Earnings Growth Penalize Rating” published on December 01, 2017 as well as Investorplace.com‘s news article titled: “3 Big Stock Charts for Monday: Bank of America Corp (BAC), Bristol-Myers …” with publication date: December 04, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.